M&T Bank Corp Decreases Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

M&T Bank Corp cut its stake in United Therapeutics Co. (NASDAQ:UTHR) by 1.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,135 shares of the biotechnology company’s stock after selling 59 shares during the period. M&T Bank Corp’s holdings in United Therapeutics were worth $1,124,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Meiji Yasuda Asset Management Co Ltd. grew its holdings in United Therapeutics by 1.6% in the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company’s stock valued at $652,000 after buying an additional 33 shares in the last quarter. Toronto Dominion Bank grew its holdings in shares of United Therapeutics by 0.8% in the second quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company’s stock valued at $1,441,000 after purchasing an additional 37 shares during the period. ClariVest Asset Management LLC grew its holdings in shares of United Therapeutics by 120.0% in the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 42 shares during the period. Benjamin F. Edwards & Company Inc. raised its stake in United Therapeutics by 14.0% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 42 shares during the period. Finally, First Citizens Bank & Trust Co. boosted its holdings in United Therapeutics by 1.8% in the 3rd quarter. First Citizens Bank & Trust Co. now owns 2,681 shares of the biotechnology company’s stock valued at $961,000 after purchasing an additional 48 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Trading Up 0.1 %

Shares of NASDAQ UTHR opened at $361.81 on Monday. The stock has a market cap of $16.15 billion, a P/E ratio of 15.89, a PEG ratio of 1.05 and a beta of 0.54. The business’s fifty day simple moving average is $369.94 and its 200-day simple moving average is $342.71. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. During the same quarter last year, the company earned $5.38 EPS. United Therapeutics’s revenue for the quarter was up 22.9% compared to the same quarter last year. On average, equities analysts forecast that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Insider Buying and Selling

In other United Therapeutics news, EVP Paul A. Mahon sold 7,700 shares of the firm’s stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $374.37, for a total value of $2,882,649.00. Following the sale, the executive vice president now directly owns 36,710 shares in the company, valued at $13,743,122.70. This trade represents a 17.34 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO James Edgemond sold 7,796 shares of United Therapeutics stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $354.04, for a total value of $2,760,095.84. Following the sale, the chief financial officer now directly owns 4,264 shares of the company’s stock, valued at $1,509,626.56. This trade represents a 64.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 119,340 shares of company stock worth $44,765,530 over the last 90 days. 11.90% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Argus raised their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Wells Fargo & Company raised their target price on United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 20th. Jefferies Financial Group upped their price target on United Therapeutics from $315.00 to $432.00 and gave the company a “buy” rating in a research note on Monday, September 23rd. The Goldman Sachs Group raised their price objective on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research report on Friday, November 1st. Finally, Oppenheimer upped their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $370.86.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.